Inferra AI / Company / INDV
Indivior Pharmaceuticals, Inc.
INDV · Health Care
Last earnings Oct 29, 2026
Key results
Total Net revenuequarter
$356 Million
Total Net Revenue of $356 Million,
SEC original ↗Indivior Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026
Net revenuequarter
$267 Million
Net Revenue of $267 Million in Q3 26, Up 22%
SEC original ↗Indivior Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026
Growthquarter
Up 22%
Net Revenue of $267 Million in Q3 26, Up 22%
SEC original ↗Indivior Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026
YoY Record Quarterly net incomequarter
$137 Million
YoY Record Quarterly Net Income of $137 Million and
SEC original ↗Indivior Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026
Record Non-GAAP net incomequarter
$161 Million
Record Non-GAAP Net Income of $161 Million in
SEC original ↗Indivior Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026
Revenuequarter
22%
We achieved record financial performance in the third quarter, including SUBLOCADE net revenue growth of 22% year-over-year and adjusted EBITDA margin of 59%, up 2100 basis points year-over-year, said Ryan Preblick, Chief Financial Officer.
SEC original ↗Indivior Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026
Grew total SUBLOCADE net revenue 22% year-over-year to $267 million.
SEC original ↗Indivior Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026
SUBLOCADE net revenue increased 24% year-over-year to $252 million versus the prior year, primarily driven by 17% dispense unit volume growth.
SEC original ↗Indivior Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026
Financial Results for Quarter Ended September 30, 2026 : Total net revenue was $356 million for the quarter ended September 30, 2026 (the 2026 quarter), compared to $314 million for the quarter ended September 30, 2025 (the 2025 quarter), representing a 13% increase year-over-year.
SEC original ↗Indivior Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026
AI analysis
Q3 2026 · reported Oct 29, 2026
Based on: Earnings release + parent 8-K — transcript not held
The quarter in charts
Guidance ladder — revenue
Delivered vs the company's guided range
EX-99 · Oct 29, 2026 Guide as stated by the company; range and midpoint computed from the stated figure.
Headline figures
| Metric | Q3 2026 | Prior qtr | Year ago |
|---|---|---|---|
| Total Net revenue | $356 Million | — | — |
| Net revenue | $267 Million | — | — |
| Growth | Up 22% | — | — |
| YoY Record Quarterly net income | $137 Million | — | — |
| Record Non-GAAP net income | $161 Million | — | — |
| Revenue | 22% | — | — |
Guidance · company-stated
“* $ 430 million to $450 million”
“* $ 700 million to $740 million”
Guidance stated in the release for FY 2026; figures as stated.
Capital allocation
In September 2026, Indivior announced that its Board of Directors declared a special cash dividend contingent upon closing of the pending merger transaction with Supernus.
Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of factors, including but not limited to: market disruptions or unanticipated delays; lower than expected future sales of our products; greater than expected impacts from competition; and unanticipated costs including the effects of potential tariffs and potential retaliatory tariffs; the effect of additional indebtedness incurred to fund the special cash dividend; potential business disruption and diversion of management attention; difficulties integrating the businesses; and potential failure to realize anticipated benefits and synergies.
What changed vs last quarter
- Guide midpoint vs latest-quarter revenue +263.8% computed from stated figures
Event summary
I want to thank the Indivior team for their commitment and hard work that generated these results and made the transaction with Supernus possible
Based on: Earnings release + parent 8-K — transcript not held
Guidance & outlook
Net Revenue: “Net Revenue $ 1,295 million to $1,365 million”
Operating Expenses: “Operating Expenses* $ 430 million to $450 million”
Adjusted EBITDA: “Adjusted EBITDA* $ 700 million to $740 million”
Net Revenue (“FY 2026”)
“1 FY 2026 Guidance Net Revenue $ 1,295 million to $1,365 million Total SUBLOCADE Net Revenue $ 1,010 million to $1,050 million Non-GAAP Operating Expenses* $ 430 million to $450 million Adjusted EBITDA* $ 700 million to $740 million * We did not provide the forward-looking U.”
Operating Expenses (“FY 2026”)
“1 FY 2026 Guidance Net Revenue $ 1,295 million to $1,365 million Total SUBLOCADE Net Revenue $ 1,010 million to $1,050 million Non-GAAP Operating Expenses* $ 430 million to $450 million Adjusted EBITDA* $ 700 million to $740 million * We did not provide the forward-looking U.”
Adjusted EBITDA (“FY 2026”)
“1 FY 2026 Guidance Net Revenue $ 1,295 million to $1,365 million Total SUBLOCADE Net Revenue $ 1,010 million to $1,050 million Non-GAAP Operating Expenses* $ 430 million to $450 million Adjusted EBITDA* $ 700 million to $740 million * We did not provide the forward-looking U.”
Guidance stated in the release for FY 2026; figures as stated.
Capital allocation
In September 2026, Indivior announced that its Board of Directors declared a special cash dividend contingent upon closing of the pending merger transaction with Supernus.
SEC original ↗Indivior Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026
Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of factors, including but not limited to: market disruptions or unanticipated delays; lower than expected future sales of our products; greater than expected impacts from competition; and unanticipated costs including the effects of potential tariffs and potential retaliatory tariffs; the effect of additional indebtedness incurred to fund the special cash dividend; potential business disruption and diversion of management attention; difficulties integrating the businesses; and potential failure to realize anticipated benefits and synergies.
SEC original ↗Indivior Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026
Strategy & priorities
About Indivior As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease.
SEC original ↗Indivior Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026
Risks & headwinds
Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of factors, including but not limited to: market disruptions or unanticipated delays; lower than expected future sales of our products; greater than expected impacts from competition; and unanticipated costs including the effects of potential tariffs and potential retaliatory tariffs; the effect of additional indebtedness incurred to fund the special cash dividend; potential business disruption and diversion of management attention; difficulties integrating the businesses; and potential failure to realize anticipated benefits and synergies.
SEC original ↗Indivior Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026
Reconciliation of GAAP to non-GAAP financial information Three Months Ended September 30, Nine Months Ended September 30, 2026 2025 2026 2025 GAAP operating expenses $ 125 $ 187 $ 398 $ 521 Stock-based compensation 8 6 28 21 Corporate initiative transition 1 14 35 38 41 Litigation settlement expense 1 Less: Adjustments in operating expenses 22 42 67 62 Non-GAAP operating expenses $ 103 $ 145 $ 331 $ 459 1 Includes severance, consulting, impairment, and costs related to planned facility closures.
SEC original ↗Indivior Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026
GAAP metrics as a result of the uncertainty and potential variability of reconciling items.
SEC original ↗Indivior Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026
By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future.
SEC original ↗Indivior Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026
What changed vs prior quarter
Total Net revenue — prior quarter passage and this quarter's passage are both cited.
SEC original ↗Indivior Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026
Net revenue — prior quarter passage and this quarter's passage are both cited.
SEC original ↗Indivior Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026
Record Non-GAAP net income — prior quarter passage and this quarter's passage are both cited.
SEC original ↗Indivior Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026
Earnings deck slides
0 decks with slide viewIndivior Pharmaceuticals, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Indivior Pharmaceuticals, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Indivior Pharmaceuticals, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Indivior Pharmaceuticals, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Indivior Pharmaceuticals, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Indivior Pharmaceuticals, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Indivior Pharmaceuticals, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
34 documentsEarnings releases
8 documentsPresentations
7 documents
Transcripts
0 documentsNo transcripts for Indivior Pharmaceuticals, Inc. are held in this edition of the library.
Mentioned by
1 companyOther tracked companies whose held documents mention Indivior Pharmaceuticals, Inc. by name or ticker. A mention is counted once per document, from the document text the library holds.
Supernus Pharmaceuticals, Inc. (SUPN)
“ raising its full year 2026 financial guidance. • Announced today agreement to merge with Indivior Pharmaceuticals, Inc. (Indivior) creating a diversified… … the same period in 2025. The change was primarily due to a non-cash $54.9 million intangible”
See also the earnings calendar for every tracked company’s next earnings date.